ArticleFrontiers in oncology2026
Mortality trends of endometrial cancer in the female adult population of the United States from 1999 to 2020.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine trends in endometrial cancer (EC) mortality among U.S. adult women from 1999 to 2020, with particular attention to the acceleration after 2013, and to assess disparities by race/ethnicity, urbanization, age, and geography. Methods: EC mortality data (ICD-10: C54) were extracted from the CDC WONDER database. Age-adjusted mortality rates (AAMRs) per 100,000 (2000 U.S. standard population) were calculated annually from 1999 to 2020. Joinpoint regression was used to estimate annual percent changes (APCs) and identify inflection points. Subgroup analyses were stratified by race/ethnicity, urbanization level (2013 NCHS classification), age group, and census region/state. Results: EC deaths increased 134% (2.34-fold), from 3,087 in 1999 to 7,230 in 2020. The joinpoint analysis showed stable phase from 1999 to 2013 (APC = -0.22; 95% CI, -0.49 to 0.04) followed by a sharp rise from 2013 to 2020 (APC = 6.25; 95% CI, 5.62 to 6.88). Black women had the highest mortality rate (5.41 per 100,000), followed by White, Asian, and American Indian/Alaska Native women. Age-related trends showed a significant rise in mortality, with the steepest increases observed in women aged 65+ years. Geographic variation was also observed, with the Northeast and Urban areas exhibiting high mortality rates. Conclusion: Endometrial cancer (EC) mortality among women has increased markedly since 2013, in particular for Black women, older people (aged 65+) and urban people. These findings underscore the urgent need for risk reduction and early detection strategies in high-burden populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.